title: Activation of a NADH dehydrogenase in the human erythrocyte by beta-adrenergic agonists: possible involvement of a G protein in enzyme activation.
abstract: NADH dehydrogenase in the plasma membrane transfers electrons from NADH to external oxidants like ferricyanide, through pathways which are linked to metabolic processes in the cell. Hormone binding to specific sites (receptors) can modify the enzyme activity, suggesting a direct or indirect coupling between the redox system and the hormone receptors. Reduction of external ferricyanide to ferrocyanide by human erythrocytes was stimulated by beta-adrenergic agonists (adrenaline, ritodrine and isoxsuprine), this effect being dependent upon concentration and pH. The agonist-stimulatory effect was attenuated in the presence of metoprolol (10(-4) M), a beta-adrenergic antagonist, and was not modified in the presence of prazosin, an alpha-adrenergic antagonist, suggesting that modification of the redox activity is mediated by binding of the agonists to beta-adrenergic receptors present in the human erythrocytes. Basal and agonist-dependent activities were inhibited in the presence of sulfhydryl reagents p-chloromercuribenzoate (PCMB, 10(-5) M) and N-ethylmaleimide (NEM, 10(-3) M), indicating the involvement of -SH groups. Inactivation by NEM was reversed by washing the cells with GTP (10(-3) M) and GTP gamma S (10(-4) M), suggesting that the specific alkylated -SH group(s) is located on a G protein in the hormone-receptor-G-protein complex. The human erythrocytes contain G proteins, displaying both guanine-nucleotide-binding properties and GTPase activity. Fluoride (10(-2) M) and fluoroaluminate (AlF4- (F-, 10(-2) M + Al3+, 10(-5) M), G protein activators, enhanced the basal and agonist-dependent activities, suggesting the involvement of G proteins in this system. The overall results indicated that one of the coupling components between the hormonal receptors and the redox system is probably a G protein, and the mechanism of enzyme activation after hormone binding to the receptor is based on the redox state of cysteine residues probably within the receptor-G-protein complex.
authors.affiliation: Central Analysis Laboratory, Aveiro University, Portugal.
authors.forename: F
authors.initials: F
authors.lastname: Marques
authors.forename: M P
authors.initials: MP
authors.lastname: Bicho
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D004837:Epinephrine / Q000494:pharmacology; D004912:Erythrocytes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D005292:Ferricyanides / Q000097:blood; D019204:GTP-Binding Proteins / Q000097:blood*; D006801:Humans; D066298:In Vitro Techniques; D007556:Isoxsuprine / Q000494:pharmacology; D008790:Metoprolol / Q000494:pharmacology; D009245:NADH Dehydrogenase / Q000097:blood*; D009247:NADH, NADPH Oxidoreductases / Q000097:blood; D010084:Oxidation-Reduction; D011224:Prazosin / Q000494:pharmacology; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000378:metabolism; D012312:Ritodrine / Q000494:pharmacology; D015398:Signal Transduction; D013438:Sulfhydryl Compounds / Q000097:blood
chemical_list: D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D005292:Ferricyanides; D011943:Receptors, Adrenergic, beta; D013438:Sulfhydryl Compounds; C007931:hexacyanoferrate III; D009247:NADH, NADPH Oxidoreductases; C014227:ferricyanide reductase; D009245:NADH Dehydrogenase; D019204:GTP-Binding Proteins; D008790:Metoprolol; D012312:Ritodrine; D007556:Isoxsuprine; D011224:Prazosin; D004837:Epinephrine